NexGen Medical Systems, Inc.
NexGen seeks $750,000 to increase sales of a breakthrough FDA-approved medical device that removes blood clots in DVT and stroke patients
NexGen's experienced management team is focused on commercializing a total procedural solution for the removal of blood clots. NexGen is raising $750,000 to increase sales of its XCOIL product line to interventional physicians who treat patients with DVT or stroke. In 24 months, we expect to be at a major inflection point in valuation in line to pursue a liquidity event through acquisition by a large med-tech company at an attractive valuation.